We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Kinase Inhibitor Online Database Will Assist Drug Developers

By LabMedica International staff writers
Posted on 14 Nov 2011
A recent paper described the establishment of a free on-line database that will allow drug developers to analyze the complex interactions between kinases and their inhibitors, which will aid in developing cancer drugs that block specific disease-related kinases while avoiding major adverse side effects.

Investigators at the Fox Chase Cancer Center (Philadelphia, PA, USA) have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 kinases. More...
Among these enzymes are many that have been linked to the development of cancer and other diseases.

Quantitative analyses reported in the October 30, 2011, online edition of the journal Nature Biotechnology revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.

“These results have pushed the field closer to finding truly specific inhibitors of the processes that drive cancer,” said senior author Dr. Jeffrey R. Peterson, associate professor of cancer biology at the Fox Chase Cancer Center. “We now have a collection of kinase inhibitors that are better characterized and understood than any other library. The next step is to use this information to identify specific, effective therapies that stop cancer in its tracks while avoiding healthy processes.”

“The fact that kinase inhibitors target multiple kinases may actually be a good thing,” said Dr. Peterson. “It may not be possible to develop a successful drug against one kinase. Indeed, some kinase inhibitors that are effective in cancer are known to target multiple kinases.”

The kinase inhibitor library is available online to the research community at no charge.

Related Links:
Fox Chase Cancer Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Manual Pipetting Aid
Pipette Controllers macro
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.